News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zonagen (ZONA) Announces Positive Top-Line Results Of Androxal(TM) Study


2/3/2006 11:13:36 AM

THE WOODLANDS, Texas--(BUSINESS WIRE)--Feb. 3, 2006--Zonagen, Inc. (Nasdaq:ZONA) and (PCX:ZONA), a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders, today announced positive top-line results of an open-label study of Androxal(TM), the company's candidate for the treatment of testosterone deficiency. This study was designed to evaluate the effect of Androxal(TM) on the testosterone levels of 13 men with normal, borderline or low testosterone.

Read at BioSpace.com
Read at AP


comments powered by Disqus
BioSpace.com
AP
Zonagen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES